Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from October 24, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 22, 2026.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$86.81 Published $96.40 Target $109.18 Window close $112.90 Peak
$85.04 – $86.51Entry zone — fair-value band
$86.81Published — price the day we called it
$96.40Target — the price the thesis aimed for
$112.90Peak — highest point inside the window, not a realized return
$109.18Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 28 days.

Peak price
$112.90
peak on January 8, 2026 — not a realized return
Peak gain
+30.1%
peak, from the publication price
Window close
$109.18
end-of-window price, context only
Days to target
28
Window
October 24, 2025 – January 22, 2026

The thesis — published October 24, 2025

Predicted growth
+12%
over the measurement window
Target price
$96.40
the price the thesis aimed for
Entry zone
$85.04 – $86.51
the fair-value band we waited for
Price at publication
$86.81
published October 24, 2025
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck looks like a steady grower that can hold up when markets are choppy. Signs of rising interest from buyers line up with a strong 93 percent score from a respected stock model. Forecasts for fast growth in U.S. lipid nanoparticle uses could help over time. In the next 0-3 months, the upside seems modest with smaller pullbacks than many tech stocks. Keep an eye on drug patent expirations and pricing rules.

Primary drivers

  • More buyers than usual and improving mood among investors supports price now
  • High 93 percent score from a respected stock-picking checklist used by pros
  • Expected growth in lipid nanoparticle uses could lift future sales
  • Stable cash coming in from key drugs helps steady the business over time

How it played out

MRK: target reached in 28 days

Lyra published MRK at 86.81 on 2025-10-24 with a short-term 12 percent growth expectation. The thesis pointed to stronger buyer interest, improving investor mood, a 93 percent stock-model score, expected growth in lipid nanoparticle uses, and stable cash from key drugs. It also noted patent expirations and pricing rules as risks.

Inside the window, the stock reached the 96.4 target in 28 days. It kept rising to a 112.9 peak on 2026-01-08, a 30.1 percent gain from the published price. It ended the window at 109.18. The thesis played out and then some.

What happened during the window

On 2025-10-30, Merck reported third-quarter results. Coverage said sales reached $17.28 billion and adjusted earnings were $2.58 per share. On 2026-01-09, the Wall Street Journal reported that Merck was in talks to buy Revolution Medicines in a deal valued around $30 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.